{"DataElement":{"publicId":"7799720","version":"1","preferredName":"Primary Gleason Score For Prostate Cancer Category","preferredDefinition":"The Primary Gleason score as defined by the most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen.","longName":"2782935v1.0:7799719v1.0","context":"MCL","contextVersion":"1","DataElementConcept":{"publicId":"2782935","version":"1","preferredName":"Gleason Score Primary Gleason Score For Prostate Cancer","preferredDefinition":"A system of grading prostate cancer cells to determine the best treatment and to predict how well a person is likely to do. A low Gleason score means the cancer cells are very similar to normal prostate cells; a high Gleason score means the cancer cells are very different from normal. _definition pending","longName":"2547908v1.0:2431249v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2547908","version":"1","preferredName":"Gleason Score for Prostate Cancer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"C28084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-081C-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"SBREXT","dateModified":"2017-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431249","version":"1","preferredName":"Primary Gleason Score For Prostate Cancer","preferredDefinition":"definition pending","longName":"C48603","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Gleason Pattern","conceptCode":"C48603","definition":"The most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE7F0-E041-3560-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5691D366-7A38-1E65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"TAYLORT","dateModified":"2017-08-23","changeDescription":"9/28/10 Released for use in caTissue Suite version 1.1 and/or 1.2 per owners direction.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7799719","version":"1","preferredName":"Gleason Score for Prostate Cancer Category","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._A grouping of items based on some commonality or by user defined characteristics","longName":"7799719v1.0","context":"MCL","contextVersion":"1","type":"Enumerated","dataType":"NUMBER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not reported","valueDescription":"Not Reported","ValueMeaning":{"publicId":"2572231","version":"1","preferredName":"Not Reported","longName":"2572231","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-11-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEF68F75-CCC3-0CC0-E053-4EBD850A86AA","beginDate":"2021-10-22","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEF68F75-CCCD-0CC0-E053-4EBD850A86AA","beginDate":"2021-10-22","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","deletedIndicator":"No"},{"value":"1","valueDescription":"Gleason Pattern 1","ValueMeaning":{"publicId":"2925235","version":"1","preferredName":"Gleason Pattern 1","longName":"2925235","preferredDefinition":"A pattern of prostate carcinoma characterized by the presence of a well circumscribed nodule of separate glands which are closely packed. There is no infiltration of the surrounding parenchyma. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Pattern 1","conceptCode":"C28085","definition":"A pattern of prostate carcinoma characterized by the presence of a well circumscribed nodule of separate glands which are closely packed. There is no infiltration of the surrounding parenchyma. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FDC7D18-C13D-DC43-E040-BB89AD431DD5","latestVersionIndicator":"Yes","beginDate":"2009-07-29","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-07-29","modifiedBy":"ONEDATA","dateModified":"2009-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEF68F75-CCD7-0CC0-E053-4EBD850A86AA","beginDate":null,"endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","deletedIndicator":"No"},{"value":"2","valueDescription":"Gleason Pattern 2","ValueMeaning":{"publicId":"2925236","version":"1","preferredName":"Gleason Pattern 2","longName":"2925236","preferredDefinition":"A pattern of prostate carcinoma characterized by the presence of glands that are more loosely arranged and less uniform compared to Gleason pattern 1. Minimal invasion of the surrounding parenchyma may be present. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Pattern 2","conceptCode":"C28086","definition":"A pattern of prostate carcinoma characterized by the presence of glands that are more loosely arranged and less uniform compared to Gleason pattern 1. Minimal invasion of the surrounding parenchyma may be present. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FDC7D18-C15F-DC43-E040-BB89AD431DD5","latestVersionIndicator":"Yes","beginDate":"2009-07-29","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-07-29","modifiedBy":"ONEDATA","dateModified":"2009-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEF68F75-CCE0-0CC0-E053-4EBD850A86AA","beginDate":null,"endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","deletedIndicator":"No"},{"value":"3","valueDescription":"Gleason Pattern 3","ValueMeaning":{"publicId":"2925237","version":"1","preferredName":"Gleason Pattern 3","longName":"2925237","preferredDefinition":"A pattern of prostate carcinoma characterized by the presence of glands that are infiltrative and vary in size and shape. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Pattern 3","conceptCode":"C28087","definition":"A pattern of prostate carcinoma characterized by the presence of glands that are infiltrative and vary in size and shape. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FDC7D18-C181-DC43-E040-BB89AD431DD5","latestVersionIndicator":"Yes","beginDate":"2009-07-29","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEF68F75-CCE9-0CC0-E053-4EBD850A86AA","beginDate":null,"endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","deletedIndicator":"No"},{"value":"4","valueDescription":"Gleason Pattern 4","ValueMeaning":{"publicId":"2925238","version":"1","preferredName":"Gleason Pattern 4","longName":"2925238","preferredDefinition":"A pattern of prostate carcinoma characterized by the presence of fused, cribriform, or poorly defined glands. There is partial loss of normal epithelial polarity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Pattern 4","conceptCode":"C28088","definition":"A pattern of prostate carcinoma characterized by the presence of fused, cribriform, or poorly defined glands. There is partial loss of normal epithelial polarity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FDC7D18-C1A3-DC43-E040-BB89AD431DD5","latestVersionIndicator":"Yes","beginDate":"2009-07-29","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-07-29","modifiedBy":"ONEDATA","dateModified":"2009-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEF68F75-CCF2-0CC0-E053-4EBD850A86AA","beginDate":null,"endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","deletedIndicator":"No"},{"value":"5","valueDescription":"Gleason Pattern 5","ValueMeaning":{"publicId":"2925239","version":"1","preferredName":"Gleason Pattern 5","longName":"2925239","preferredDefinition":"A pattern of prostate carcinoma characterized by almost complete loss of epithelial polarity and luminal differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Pattern 5","conceptCode":"C28089","definition":"A pattern of prostate carcinoma characterized by almost complete loss of epithelial polarity and luminal differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FDC7D18-C1C5-DC43-E040-BB89AD431DD5","latestVersionIndicator":"Yes","beginDate":"2009-07-29","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEF68F75-CCFB-0CC0-E053-4EBD850A86AA","beginDate":null,"endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5936782","version":"1","preferredName":"Gleason Score for Prostate Cancer Category","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C28084:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"576E72DD-5EE7-3C5F-E053-F662850A5B33","latestVersionIndicator":"Yes","beginDate":"2017-08-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-23","modifiedBy":"ONEDATA","dateModified":"2017-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CEF68F75-CCAB-0CC0-E053-4EBD850A86AA","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"COLBERTM","dateModified":"2022-03-01","changeDescription":"3/1/22 mr Released per SME.   10/22/21 mr Created from NCI Standard VD in order to add Unknown and NR for MCL PCA prostate.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781145","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001794","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"gleason_score_dominant_nodule","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"MCL-Template Name","type":"Data Collection Template","description":"prostate_v0_13aug2020.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"},{"name":"Gleason score of dominant nod","type":"Preferred Question Text","description":"Gleason score of dominant nodule","url":null,"context":"MCL"}],"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CEF68F75-CD0A-0CC0-E053-4EBD850A86AA","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-22","modifiedBy":"COLBERTM","dateModified":"2022-02-25","changeDescription":"2/25/22 mr Released per SME.   10/26/21 mr Added ref doc, alt name, CSI per DCT.  10/22/21 mr Created for MCL PCA prostate.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}